Picture of BioXcel Therapeutics logo

BTAI BioXcel Therapeutics Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for BioXcel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K8-K
Standards:
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0000.3751.38
Cost of Revenue
Gross Profit0.3550.12
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses33.682.3107160173
Operating Profit-33.6-82.3-107-160-172
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-33-82.2-107-166-179
Net Income After Taxes-33-82.2-107-166-179
Net Income Before Extraordinary Items
Net Income-33-82.2-107-166-179
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-33-82.2-107-166-179
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-2.02-3.79-4.05-5.92-6